Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction

Rhea-AI Summary

Wellgistics (NASDAQ:WGRX) said its President & Interim-CEO outlined a strategic pivot toward selling prescription drugs directly to patients via its online pharmacy and expanding its EinsteinRx AI platform beyond dispensing optimization.

The company cited exclusive technology licensing for PharmacyChain™, partnerships including NFL Alumni Health and Tollo Health, and plans to deploy telemedicine, diagnostic testing, and benefits-verification tools.

News Market Reaction – WGRX

-1.80%

7 alerts

-1.80% News Effect

+13.2% Peak Tracked

-3.8% Trough Tracked

-$274K Valuation Impact

$15M Market Cap

0.1x Rel. Volume

On the day this news was published, WGRX declined 1.80%, reflecting a mild negative market reaction. Argus tracked a peak move of +13.2% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $274K from the company's valuation, bringing the market cap to $15M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Diabetic/obese GLP-1 patients: over 36 million+ (12%+ of US population) Long COVID patients: over 18 million+ (6% of US population) Annual viral infections: 6–10 per person; 300 million+ Americans +5 more

8 metrics

Diabetic/obese GLP-1 patients over 36 million+ (12%+ of US population) Patients currently on GLP-1 medication targeted via Forzet

Long COVID patients over 18 million+ (6% of US population) Population targeted via Tollovid dietary supplement

Annual viral infections 6–10 per person; 300 million+ Americans Target population for Galectovid medical food product

52-week high $7.04 Pre-news trading range; WGRX near 52-week low

52-week low $0.157 Price recently traded just above this level

Price change -13.24% 24h move before/into shareholder letter release

Relative volume 12.15× Today’s volume vs 20-day average

Market cap $19,619,149 Equity value at pre-news price

Market Reality Check

Price: $0.1634 Vol: Volume 60,628,347 is abou...

high vol

$0.1634 Last Close

Volume Volume 60,628,347 is about 12.15× the 20-day average of 4,988,664, signaling unusually heavy trading ahead of and into this update. high

Technical Price at $0.1664 is trading below the 200-day MA ($0.79) and sits 97.64% under the 52-week high, near the 52-week low.

Peers on Argus

WGRX was down 13.24% while key peers showed mixed, mostly modest moves (e.g., PE...

1 Up

WGRX was down 13.24% while key peers showed mixed, mostly modest moves (e.g., PETS and HITI at -1.22%, HKPD at -0.76%, SCNX at +6.35%, SSY at +9.31%). The magnitude of WGRX’s decline, combined with peer_momentum data showing only one peer in momentum, points to a stock-specific reaction rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	EBV integration deal	Positive	+5.4%	Preferred pricing and new EBV revenue stream via EinsteinRx and PharmacyChain.
Mar 09	Forzet launch	Positive	+5.8%	Launch of Forzet medical food for GLP‑1 muscle loss through pharmacy channels.
Mar 05	Blockchain platform pick	Positive	-9.2%	Selection of multiple blockchain platforms to build PharmacyChain serialization.
Feb 23	HaaS partnership	Positive	+9.8%	Expanded Datavault AI partnership for tokenized patient data and telemedicine links.
Feb 18	Mental health AI deal	Positive	+0.3%	Strategic investment in mental health AI startup tied to EinsteinRx expansion.

Pattern Detected

Recent positive strategic and partnership news often saw positive next-day moves, though the March 5 blockchain/serialization update drew a negative reaction, showing investors can sell into even upbeat announcements.

Recent Company History

Over the last month, WGRX has issued a series of technology- and patient-care-focused updates. On Feb 18 and Feb 23, it highlighted AI, mental health, and expanded Datavault AI partnerships. Early March brought PharmacyChain™ blockchain build-out (Mar 5), launch of GLP‑1 muscle-loss medical food Forzet (Mar 9), and an eligibility/benefits verification deal (Mar 11). Those events generally produced positive single‑digit price moves, with one notable selloff on the serialization news, framing today’s strategic letter within an already active transformation narrative.

Market Pulse Summary

This announcement outlines a pivot toward patient‑centric, direct‑to‑consumer care using EinsteinRx™...

Analysis

This announcement outlines a pivot toward patient‑centric, direct‑to‑consumer care using EinsteinRx™, PharmacyChain™, telemedicine, and partnerships spanning NFL Alumni Health and Tollo Health. It connects with recent moves into GLP‑1 muscle‑loss support and blockchain‑based serialization, emphasizing access to over 36 million diabetic/obese and 18 million Long COVID patients. Investors may watch how Wellgistics executes on telehealth integration, partner onboarding, and monetization of eligibility/benefits verification and new therapeutics within this emerging ecosystem.

Key Terms

blockchain-enabled smart contracts, telemedicine, online pharmacy, tokenize, +4 more

8 terms

blockchain-enabled smart contracts technical

"its patented blockchain-enabled smart contracts platform PharmacyChain™"

Blockchain-enabled smart contracts are self-executing agreements stored on a digital ledger that automatically enforce their terms when certain conditions are met. They function like digital vending machines: once the predefined rules are satisfied, the contract completes without needing a third party. For investors, these contracts can reduce costs, increase transparency, and ensure transactions happen reliably and instantly.

telemedicine medical

"from physicians through telemedicine, it is clear that technology"

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

online pharmacy technical

"becoming a seller of prescription drugs and related services directly to patients via the Company's online pharmacy"

An online pharmacy sells prescription and over-the-counter medicines through a website or mobile app, processing prescriptions, payments and typically arranging home delivery or local pickup. It matters to investors because it can change how people buy drugs — offering convenience, lower per-unit costs and faster growth potential — while exposing a business to regulatory rules, insurance payment terms and competitive pressure, all of which affect revenue and profit margins.

tokenize technical

"that will allow us not only to tokenize prescription drug data, but also data of each data aspect"

To tokenize is to convert ownership or rights in a real-world asset (like a building, a bond, or a piece of art) into digital tokens recorded on a shared electronic ledger, similar to turning a whole object into many collectible trading cards that each represent a slice of the item. For investors this can make large or illiquid assets easier to buy, sell or split into smaller pieces, speed up transfers, and increase transparency, while also introducing new technology and regulatory risks.

electronic patient records medical

"aggregation of electronic patient records (EHD) data such as prior diagnoses"

Electronic patient records are digital versions of a person’s medical history, test results, prescriptions and treatment notes stored and shared securely across healthcare systems — like a locked, searchable filing cabinet for health information. For investors, they matter because adoption affects healthcare providers’ operating costs, efficiency, regulatory compliance and exposure to data-breach risk, and they create market opportunities for software vendors, hardware suppliers and services that enable secure data exchange and analytics.

3CL protease medical

"via 3CL protease cleansing dietary supplement Tollovid™"

3CL protease is an enzyme viruses use to cut long viral protein chains into the smaller parts needed to assemble new virus particles; it is often called the “main protease.” Investors care because blocking this molecular scissors can stop viral replication, making 3CL protease a prime drug target for antiviral therapies. Think of it like disabling the key machine on a factory line—successful inhibitors can create value by enabling effective treatments.

dietary supplement medical

"3CL protease cleansing dietary supplement Tollovid™"

A dietary supplement is a product taken by mouth that adds nutrients or other ingredients—such as vitamins, minerals, herbs, amino acids, or enzymes—to the diet; it is intended to support normal bodily functions, not to diagnose, treat, cure, or prevent disease. Investors care because these products sit between food and drugs in regulation, so sales, branding, quality control, labeling claims and regulatory scrutiny can drive demand, margins, recalls and legal risk much like a fast-moving consumer staple.

medical food medical

"via medical food Forzet™ and the over 18 million+"

Specialized nutritional products designed to be used under a health professional’s supervision to manage specific medical conditions that have unique dietary needs. Think of them as a tailored meal plan in a bottle or package: not a medicine and not an everyday food, but a regulated product intended to address nutrition gaps tied to a disease. Investors track them because they follow different approval, labeling, and reimbursement rules, which affect market size and sales channels.

AI-generated analysis. Not financial advice.

TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders.

The prescription drug and broader healthcare landscapes in the United States are rapidly changing. From the direct involvement of the federal government in providing discount cards for prescription drugs via to direct to consumers (DTC) online platform TrumpRx, to major pharmaceutical manufacturers offering prescription obesity drugs DTC through their own online pharmacies, to increasing percentages of patients receiving prescriptions for obesity and other drugs from physicians through telemedicine, it is clear that technology is rapidly changing how Americans engage with the healthcare system. This emerging shift in the healthcare market that gained significant momentum during the height of the COVID-19 pandemic has significant long-term consequences for independent pharmacies and providers throughout the country.

Here at Wellgistics Health, we have been evaluating how best to leverage our pharmaceutical distribution businesses and deep healthcare relationships to position ourselves for the healthcare system tomorrow. After thorough review, we have determined that the best path forward for us is to transition our focus towards becoming a seller of prescription drugs and related services directly to patients via the Company's online pharmacy, and to leverage our relationships with independent pharmacies and other more local service providers to coordinate patient care with a view towards expanding the scope of our industry-leading EinsteinRx artificial intelligence hub platform to enable its use in areas beyond prescription drug dispensing optimization, towards optimization of patient outcomes.

To this end, we have been strategically expanding marketing and healthcare technology relationships in preparation for this new direction. Our emerging partnership with NFL Alumni Health is set to provide us with access to a uniquely positioned group of influencers with unparalleled brand awareness and trust, capable of generating deep consumer engagement that we believe will help us elevate our new message to consumers throughout the United States in the second half of the year as football season kicks into gear. We have exclusively licensed technology from DataVault AI in preparation for the deployment of the Company's proprietary drug serialization solution PharmacyChain™ that will allow us not only to tokenize prescription drug data, but also data of each data aspect required for a prescription drug to be dispensed - which includes the aggregation of electronic patient records (EHD) data such as prior diagnoses, diagnostic testing results and other key data. We recently gained access to a proprietary lower-cost eligibility and benefits verification tool sufficiently attractive to compete for pharmacy and partner verification business in anticipation of the deployment of PharmacyChain so that there is an immediate incentive for partners to work with us as we begin to expand our healthcare ecosystem beyond pharmacy.

We are also leveraging our deep understanding of pharmacy science to position ourselves on the side of patients with respect to mitigating the side effects of prescription drugs in rapidly growing and large underserved medical conditions. To this end, the Company's partnership with Tollo Health has positioned us to target two large chronic conditions that currently experience incomplete outcomes and/or side effects from currently approved prescription drug solutions with the over 36 million+ (12%+ of US population)[1] & growing diabetic and/or obese patients currently on GLP-1 medication via medical food Forzet™ and the over 18 million+ (6% of US population)[2] suffering from Long COVID via 3CL protease cleansing dietary supplement Tollovid™. Additionally, Tollo has natural medical food product Galectovid™ that is targeted towards the 6-10 annual viral infections each American (300 million+)[3] contracts, the vast majority of which are left untreated and have been increasingly linked to later-in-life chronic diseases such as cancer, Alzheimer's disease and multiple sclerosis.

While we have made strides in this new direction, with the longer-term and medium terms outlook shaping up nicely, we are now preparing to focus on the immediate term execution phase that will position us to be able to complete this shift. To this end, we are actively preparing our telemedicine and diagnostic testing strategies, aiming to develop a closed-loop ecosystem that pharmaceutical manufacturing and other partners will be attracted to as a result of the marketing power, data generation and patient flow capabilities that will build value for their brands. We are also engaged with payers who have expressed a strong interest in being able to help shape our PharmacyChain solution to help solve key inefficiencies that currently plague the US healthcare system and result in higher costs with poor outcomes and expect to secure relationships that will allow us to begin to deploy our emerging solutions in a stepwise fashion, initially around mitigating GLP-1 related muscle loss.

We strongly believe that now is the time to take these decisive actions so that we can retool our offering for the future. We intend to fortify our relationships with the Wellgistics Pharmacy Network by making available many more tools to help pharmacists manage their patients, and expect that as pharmacies are able to confidently expand their service offerings, we will be able to enable them with products and relationships they would otherwise not have access to alone, strengthening our value proposition to them via new revenue streams at a time of compressing margins and making them an extension of our own offering where appropriate.

We believe in our mission, cognizant of the broader changes in the healthcare landscape and clear-eyed with respect to the challenges ahead.

Thank you for taking the time to read this letter, for being a shareholder and for joining us in our journey to revolutionize healthcare in America.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet™, the expected benefits of the product, the Company's plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Company's direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology.

Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Company's products and services, the Company's ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzet™ is intended to diagnose, treat, cure, or prevent any disease.

[1] https://www.statista.com/chart/35919/key-figures-usage-and-opinion-glp-1-medication-weight-loss-drugs-in-the-united-states/#:~:text=In%20mid/late%202025%2C%2012.4,surveyed%20in%202024%20and%202025.

[2] https://www.hhs.gov/longcovid/index.html

[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC10116010/

Wellgistics Media & Investor Contact:

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What strategic shift did Wellgistics (WGRX) announce on March 13, 2026?

The company is shifting to sell prescription drugs directly to patients via its online pharmacy and expand AI use. According to the company, this includes extending EinsteinRx beyond dispensing and building a closed-loop telemedicine and diagnostics ecosystem to coordinate patient care.

How will Wellgistics (WGRX) use PharmacyChain™ and when will it deploy it?

PharmacyChain™ will tokenize prescription and patient data and support drug serialization to coordinate dispensing and records. According to the company, it has exclusively licensed technology for PharmacyChain and plans stepwise deployment tied to partner integrations and verification tools.

What partnerships did Wellgistics (WGRX) highlight to support its new consumer strategy?

Wellgistics cited an emerging partnership with NFL Alumni Health and a product partnership with Tollo Health to reach consumers and target chronic conditions. According to the company, these relationships will support marketing, product distribution, and efforts to mitigate drug side effects.

Which patient conditions and products did Wellgistics (WGRX) reference in its March 13, 2026 letter?

The company named GLP-1 related diabetes/obesity and Long COVID as focus areas and referenced Forzet™, Tollovid™, and Galectovid™. According to the company, these products are positioned as medical food or dietary supplement solutions to address treatment gaps and side effects.

What operational tools is Wellgistics (WGRX) preparing to roll out to partners?

Wellgistics is preparing benefits-verification, telemedicine, diagnostic testing, and pharmacy-facing tools to drive partner adoption and patient flow. According to the company, a lower-cost eligibility and benefits verification tool was recently obtained to incentivize early partner engagement.

How does Wellgistics (WGRX) expect the consumer marketing plan to unfold in 2026?

The company expects elevated consumer engagement in the second half of 2026 leveraging NFL Alumni Health influencers and marketing campaigns. According to the company, this timing aligns with football season and aims to drive awareness for its online pharmacy and associated services.